



HEALTH PLAN FOR ACTIVE STATE OF LOUISIANA EMPLOYEES

Addition of Prescription Drug: PCSK-9 Coverage Amendment

This Amendment is issued by the Plan Administrator for the Plan document listed below, effective on and after 07/01/2024.

Schedule of Benefit: PELICAN HSA 775 40HR1698 R01/24

The Schedule of Benefits Prescription Drugs Subsection is hereby revised with removal of the following language: Proprotein convertase subtilisin/kexin type 9 (PCSK-9) inhibitors (e.g., Praluent[®], Repatha[™]) are excluded.

ALL OTHER PROVISIONS NOT CHANGED BY THIS AMENDMENT REMAIN IN FULL FORCE AND EFFECT.

Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana Inc., are independent licensees of the Blue Cross Blue Shield Association.

13LG0592 07/24